These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 29764500)
1. The role of initial Zhang L; Zhang X; He Q; Zhang R; Fan W Cancer Imaging; 2018 May; 18(1):19. PubMed ID: 29764500 [TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997 [TBL] [Abstract][Full Text] [Related]
4. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Kato T; Tsukamoto E; Nishioka T; Yamazaki A; Shirato H; Kobayashi S; Asaka M; Imamura M; Tamaki N Clin Nucl Med; 2000 Nov; 25(11):870-3. PubMed ID: 11079582 [TBL] [Abstract][Full Text] [Related]
5. Whole-body (18)F-FDG PET identifies high-risk myeloma. Durie BG; Waxman AD; D'Agnolo A; Williams CM J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548 [TBL] [Abstract][Full Text] [Related]
6. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT. Pan Q; Luo Y; Li J; Zhang S; Li F Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N; Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775 [TBL] [Abstract][Full Text] [Related]
8. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442 [TBL] [Abstract][Full Text] [Related]
9. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628 [TBL] [Abstract][Full Text] [Related]
10. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
11. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia. Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667 [TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT Metabolic Activity in a Patient With Solitary Extramedullary Plasmacytoma of the Lung. Zhang L; Zhang X; Zhang R; Fan W Clin Nucl Med; 2016 Mar; 41(3):232-4. PubMed ID: 26462042 [TBL] [Abstract][Full Text] [Related]
13. Lack of clinical impact of Liu J; Larcos G; Howle J; Veness M Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
15. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210 [TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787 [TBL] [Abstract][Full Text] [Related]
18. [Value of Pretherapeutic Ding CY; Liu HY; Guo Z; Li TN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):438-443. PubMed ID: 28446289 [TBL] [Abstract][Full Text] [Related]
19. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383 [TBL] [Abstract][Full Text] [Related]